Another IL-23 Antagonist Appears to Be Effective for Management of Psoriasis

A phase 1 study suggests efficacy, but will intravenous treatment infusions be viable?

Ustekinumab has effects on both interleukin 12 (IL-12) and IL-23, but its effects on IL-23 are believed to be responsible for the improvements observed in treated patients with psoriasis. Tildrakizumab is a novel agent (not currently FDA-approved) that targets the p19 subunit of IL-23.

To evaluate the effectiveness, safety, and pharmacokinetics of tildrakizumab in psoriasis, researchers (including one employee of the manufacturer of tildrakizumab) conducted a phase 1 study. Part 1 of the study involved 24 patients randomized 1:3 to receive either placebo or one of four ascending doses of tildrakizumab, from 0.1 mg/kg to 10 mg/kg, infused intravenously. The patients received additional infusions at 8 weeks (after safety observation in the int…

Reviewing Author

Jeffrey P. Callen, MD

Disclosures

Consultant / Advisory board XOMA; Eli Lilly; Celgene

Equity Various trust accounts

Editorial boards JAMA Dermatology; UpToDate

Leadership positions in professional societies Association of Professors of Dermatology (President-Elect)